Teresa Klinowska
I serve as a Global Product Leader in Late Stage Oncology Research and Development at AstraZeneca. In my role, I lead global development teams for oncology compounds from the start of Phase 3 clinical trials through to launch and beyond.
I am most passionate about science and people. I began my career in academia but have spent the past two decades focused on oncology research and development at AstraZeneca because I am driven to help people living with cancer. My work at AstraZeneca is a perfect combination of my passions – we have an extremely robust product pipeline underpinned by exceptional science, and we take a truly patient-centric approach.
Over the years, I have held bioscience, translational science, principle scientist, tumour strategy leadership and project leadership roles in both early and late stage development, across AstraZeneca’s oncology franchises, with recent particular focus in breast cancer. I was the early project leader of the team that discovered a targeted therapy in EGFR+ lung cancer.
I also have significant expertise in breast cancer having led the team which defined strategy for breast cancer therapy development across AstraZeneca and MedImmune. I am currently leading an estrogen receptor targeting project in Late Development Oncology and have co-authored more than 45 peer-reviewed publications including papers in Nature, Clinical Cancer Research, Cancer Discovery and J Cell Science.
Before joining AstraZeneca, I gained my PhD in cell biology and embryonic development at the University of Manchester and worked at a start-up biotech focused on wound healing.
I am passionate about making a difference by bringing new medicines and innovations to patients, working collaboratively with industry, academia and the patients themselves.
Honor
2024: 8th International PacRim Breast and Prostate Cancer Meeting
Shortlisted
2023: Finalist for AstraZeneca’s R&D award for the design and delivery of SERENA-3, a pre-surgical window of opportunity study in post menopausal women with early breast cancer (NCT04588298)
Award
2022: AstraZeneca R&D award for the design and delivery of SERENA-2, a randomised study in patients with metastatic breast cancer (NCT04214288)
CURRENT ROLE
2014 – 2019
2011 – 2014
2009 – 2011
Featured publications
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results
Ann Oncol. 2024 Aug;35(8):707-717. doi: 10.1016/j.annonc.2024.04.012. Epub 2024 May 8. Publication link.
Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC
Commun Biol. 2024 May 13;7(1):563. doi: 10.1038/s42003-024-06238-x. Publication link.
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021-December 2023)
Expert Opin Ther Pat. 2024 May;34(5):333-350. doi: 10.1080/13543776.2024.2364803. Epub 2024 Jun 12. Publication link.
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
Cancer Res. 2023 Dec 1;83(23):3989-4004. doi: 10.1158/0008-5472.CAN-23-0694. Publication link.
Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists.
J Med Chem. 2023 Feb 23;66(4):2918-2945. doi: 10.1021/acs.jmedchem.2c01964. Epub 2023 Feb 1. Publication link.
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors.
Clin Cancer Res. 2022 Jun 1;28(11):2257-2269. doi: 10.1158/1078-0432.CCR-21-3087. Publication link.
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection
Mol Oncol. 2022 May;16(10):1969-1985. doi: 10.1002/1878-0261.13150. Epub 2021 Dec 20. Publication link.
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition.
Mol Cancer Ther. 2021 Jun;20(6):1080-1091. doi: 10.1158/1535-7163.MCT-20-0961. Epub 2021 Mar 30. Publication link.
Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.
J Med Chem. 2020 Dec 10;63(23):14530-14559. doi: 10.1021/acs.jmedchem.0c01163. Epub 2020 Sep 29. Publication link.
A randomized, window of opportunity study comparing the effects of the novel oral SERD AZD9496 with fulvestrant in patients with ER+ HER2- primary breast cancer.
Robertson JF, Evans A, Henschen S, Kirwan CC, Jahan A, Kenny LM, Dixon JM, Schmid P, Kothari A, Mohamed O, Fasching PA, Cheung KL, Wuerstlein R, Carroll D, Klinowska T, Lindemann JPO, MacDonald A, Mather R, Maudsley R, Moschetta M, Nikolaou M, Roudier MP, Sarvotham T, Schiavon G, Zhou D, Zhou L, Harbeck N. Clinical Cancer Research 2020. Publication link.
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W. Cancer Discovery 2014. Publication link.
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.
Rodrik-Outmezguine VS, Okaniwa M, Yao Z, Novotny CJ, McWhirter C, Banaji A, Won H, Wong W, Berger M, de Stanchina E, Barratt DG, Cosulich S, Klinowska T, Rosen N, Shokat KM. Nature. 2016 Jun 9;534. Publication link.
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results From AZD9496 Oral SERD Phase I Trial.
Paoletti C, Schiavon G, Dolce EM, Darga EP, Carr TH, Geradts J, Hoch M, Klinowska T, Lindemann J, Marshall G, Morgan S, Patel P, Rowlands V, Sathiyayogan N, Aung K, Hamilton E, Patel M, Armstrong A, Jhaveri K, Im SA, Iqbal N, Butt F, Dive C, Harrington EA, Barrett JC, Baird R, Hayes DF. Clin Cancer Res. 2018 Dec 1 24 (23), 5860-5872. Publication link.
Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors.
Lynch JT, Polanska UM, Hancox U, Delpuech O, Maynard J, Trigwell C, Eberlein C, Lenaghan C, Polanski R, Avivar-Valderas A, Cumberbatch M, Klinowska T, Critchlow SE, Cruzalegui F, Barry ST. Mol Cancer Ther. 2018 Nov 17 (11), 2309-2319. Publication link.
A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER +/HER2 - Advanced Breast Cancer.
Hamilton EP, Patel MR, Armstrong AC, Baird RD, Jhaveri K, Hoch M, Klinowska T, Lindemann JPO, Morgan SR, Schiavon G, Weir HM, Im SA. Clin Cancer Res. 2018 Aug 1, 24 (15), 3510-3518. Publication link.
Building bridges in a series of estrogen receptor degraders: an application of metathesis in medicinal chemistry.
Scott JS, Breed J, Carbajo RJ, Davey PR, Greenwood R, Huynh HK, Klinowska T, Morrow CJ, Moss TA, Polanski R, Nissink JWM, Varnes J, Yang B. ACS Med Chem Lett. 2019 10(10):1492-1497. Publication link.
HO-1 drives autophagy as a mechanism of resistance against HER-2 targeted therapies.
Tracey N, Creedon H, Kemp AJ, Culley J, Muir M, Klinowska T, Brunton VG. Breast Cancer Res Treat. 2019. Publication link.
Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation.
Hennessy EJ, Chuaqui C, Ashton S, Colclough N, Cross DA, Debreczeni JÉ, Eberlein C, Gingipalli L, Klinowska TC, Orme JP, Sha L, Wu X. ACS Med Chem Lett. 2016 Mar 21;7(5):514-9. Publication link.
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
Guichard SM, Curwen J, Bihani T, D'Cruz CM, Yates JW, Grondine M, Howard Z, Davies BR, Bigley G, Klinowska T, Pike KG, Pass M, Chresta CM, Polanska UM, McEwen R, Delpuech O, Green S, Cosulich SC. Mol Cancer Ther. 2015 Nov;14(11):2508-18. Publication link.